Kristen Doute Says She’ll ‘Try’ Weight Loss Injections After Giving Birth
- Kristen Doute discussed post-baby body plans on the "Bitch Bible" podcast Tuesday, April 22.
- Doute is currently pregnant and expects a baby girl with Luke Broderick.
- She plans to use weight loss drugs like Ozempic after giving birth.
- Doute quipped, "If Ozempic doesn’t work then eating disorder, bring it on."
- Her remarks highlight her focus on post-pregnancy weight management strategies.
16 Articles
16 Articles
Kristen Doute Says She’ll ‘Try’ Weight Loss Injections After Giving Birth
Kristen Doute is already preparing for her post-baby body, which she said will include using weight loss drugs. The pregnant star, 42, joked that she “hopes” to develop an eating disorder after giving birth as a backup plan to slim down. “If Ozempic doesn’t work then eating disorder, bring it on,” Doute quipped during an appearance on the Tuesday, April 22, episode of the “Bitch Bible” podcast. When asked whether she’d do “injections,” Doute rep…
Deciding on weight-loss medication
With the growing popularity of weight loss medications, many people are turning to prescription options to help them achieve their health goals.Medications like Ozempic, Mounjaro, and Wegovy are among the most well-known, but how do you know which one is right for you?Ozempic (Semaglutide)Originally developed for managing type 2 diabetes, Ozempic has shown significant weight loss benefits. Ozempic works by mimicking a hormone called GLP-1, which…
A more practical and perhaps cheaper alternative to injections for diabetes and for weight loss has yielded promising results and has enormous potential
Denmark's Novo Nordisk sees shares tumble after competitor breakthrough
Shares in Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, fell sharply Tuesday following the announcement of a successful clinical trial by competitor Eli Lilly.
Daily pill could replace weight-loss shots like Ozempic and Wegovy
A daily pill developed by the US pharmaceutical company Lilly may become a convenient alternative to injectable drugs like Ozempic and Wegovy. In phase III trials it significantly lowered blood sugar and body weight in people with type 2 diabetes
Coverage Details
Bias Distribution
- 38% of the sources lean Left, 37% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
